ArticleComputational and structural biotechnology journal2026
CancerSubtypeXplore: A Modular Platform for Multiomics Cancer Subtype Prediction and Biomarker Consensus Discovery.
Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying reproducible biomarkers and cancer subtypes from large-scale multiomics data remains a challenging task, as current computational frameworks often require coding expertise and lack standardized datasets for model benchmarking and exploration. To address these limitations, we developed CancerSubtypeXplore, a modular and user-friendly platform for multiomics cancer subtype prediction and biomarker discovery. The system integrates 4 main components: (a) a dataset module providing standardized and curated multiomics datasets from 17 The Cancer Genome Atlas cancer types, including mRNA, DNA methylation, and microRNA profiles; (b) a machine learning module for automated benchmarking using classical algorithms such as support vector machines and random forests; (c) design your deep learning model module that allows users to design and train customized neural network architectures without coding; and (d) a biomarker analysis module that extracts prediction-contributed features as biomarkers from each trained model, computes their intersections, and ranks them by frequency to identify robust cross-model or cross-cancer biomarkers. Benchmark experiments demonstrate consistent subtype prediction accuracy across multiple cancer types and reveal overlapping biomarkers that may serve as potential pan-cancer signatures. CancerSubtypeXplore provides a transparent, reproducible, and extensible environment for biomedical researchers to explore multiomics datasets, evaluate diverse models, and identify robust biomarkers.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.